Durect Corp

NASDAQ:DRRX   2:15:46 PM EDT
0.70
0.00 (+0.29%)
Products

Durect And Innocoll Announce A $136 Million U.S. Licensing Agreement For Posimir® (Bupivacaine Solution)

Published: 12/22/2021 12:54 GMT
Durect Corp (DRRX) - Durect and Innocoll Announce a $136 Million U.S. Licensing Agreement for Posimir® (bupivacaine Solution).
Durect Corp - Innocoll Granted Exclusive Development and Commercialization Rights to Posimir in United States.
Durect Corp - Durect to Receive Near-term Upfront Cash Payments Totaling $6 Million, Potential Additional Milestone Payments of Up to $130 Million.
Durect Corp - Durect to Receive Tiered Low to Mid Double-digit Royalties Based on U.S. Sales.